MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ginsenoside Re

CAS No. : 52286-59-6

MCE 站：Ginsenoside Re

产品活性：Ginsenoside Re (Ginsenoside B2) 是一种 Panax notoginseng 提取物。Ginsenoside Re 可降低 β-淀粉样蛋白 (Aβ)。Ginsenoside Re 还通过抑制 JNK 和 NF-κB 发挥抗炎作用。

研究领域：Neuronal Signaling  |  NF-κB  |  MAPK/ERK Pathway  |  Metabolic Enzyme/Protease

作用靶点：Amyloid-β  |  NF-κB  |  JNK  |  Endogenous Metabolite

In Vitro: Ginsenoside Re is a well-known traditional Chinese medicine, which decreases the β-site amyloid precursor protein cleaving enzyme 1 (BACE1) mRNA ａnd protein levels ａnd inhibits BACE1 activity in the N2a/APP695 cells. Ginsenoside Re also significantly increases the PPARγ protein ａnd mRNA levels.To prevent Ginsenoside Re from having a cytotoxic effect on the N2a/APP695 cells, the cell viability is first determined by the MTT assay. The N2a/WT ａnd N2a/APP695 cells are treated with increasing concentrations of Ginsenoside Re (0-200 µM) for 24 h. Ginsenoside Re concentrations under 100 µM do not affect the viability of the N2a/WT ａnd N2a/APP695 cells, whereas the 150 µM Ginsenoside Re concentration markedly decreases the survival rate of the N2a/WT ａnd N2a/APP695 cells. Incubation with Ginsenoside Re at a 200 µM concentration for 24 h reduces the viability of the N2a/WT ａnd N2a/APP695 cells by 15.58% ａnd 26.82%, respectively. These data indicate that Ginsenoside Re treatment within the range of 0-100 µM for 24 h is safe for the N2a/WT ａnd N2a/APP695 cells (P>0.05).

In Vivo: Ginsenoside Re reduces insulin resistance in 3T3-L1 adipocytes ａnd high-fat diet (HFD) rats through inhibition of JNK ａnd NF-κB activation. Intraperitoneal injection of lipopolysaccharide (LPS) at a dose of 20 mg/kg is lethal to mice, ａnd 70% to 80% of the mice die within 60 h. However, pretreatment of the mice with Rg1 or Ginsenoside Re increases their survival rates in a dose-dependent manner. With the doses of Rg1 or Ginsenoside Re increase from 2.5 to 5 mg/kg, the survival rate is elevated from 60% to 90% (Rg1) or from 30% to 40% (Ginsenoside Re). All the mice administered Rg1 at a minimal dose of 10 mg/kg are protected from death compared to 80% survival of mice treated with an equal dose of Ginsenoside Re. To protect all the mice, 20 mg/kg Ginsenoside Re is needed. To investigate the anti-inflammatory potential of Rg1 ａnd Ginsenoside Re, 1 mg/kg Rg1 or Ginsenoside Re is injected into rats ａnd then challenged the animals with LPS. The injection procedure itself causes a transient stress-induced increase in body temperature of ~1.2°C in each group. Thereafter, LPS-challenged rats without pretreatment develope a robust biphasic fever, with the first peak reaching ~1.5°C at 2 h ａnd the second peak reaching 1.8°C at 4 h. In contrast, the temperature changes for the Rg1-, Ginsenoside Re-, ａnd TAK-242-treated groups are only 0.9, 1.2, ａnd 0.8°C at 2 h ａnd 1.3, 1.4, ａnd 1.0°C at 4 h, respectively. Pretreatment with Rg1, Ginsenoside Re, or TAK-242 significantly attenuates LPS-induced alterations in body temperature.

相关产品：Natural Product Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Metabolism/Protease Compound Library  |  Neuronal Signaling Compound Library  |  NF-κB Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  Natural Product Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Human Endogenous Metabolite Compound Library  |  Anti-Aging Compound Library  |  Antioxidants Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Medicine Food Homology Compound Library  |  Pyroptosis Compound Library  |  Traditional Chinese Medicine Monomer Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer＇s Disease Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Parkinson＇s Disease Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Transcription Factor Targeted Library  |  Food-Sourced Compound Library   |  Rapamycin  |  3-Methyladenine  |  Phorbol 12-myristate 13-acetate  |  Acetylcysteine  |  Deferoxamine mesylate  |  Bortezomib  |  5-Fluorouracil  |  SP600125  |  ATP  |  Retinoic acid  |  DAPT  |  Hydrocortisone  |  Docetaxel  |  Estradiol  |  Melatonin  |  Nicotinamide  |  Cytarabine  |  Isoprenaline hydrochloride  |  Prostaglandin E2  |  Acetaminophen  |  Pyrrolidinedithiocarbamate ammonium  |  (-)-Epigallocatechin Gallate  |  L-Ascorbic acid  |  TAK-243  |  β-Nicotinamide mononucleotide  |  Anisomycin  |  JSH-23  |  Calcitriol  |  DHEA  |  Liothyronine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。